Clinical Trials Logo

Autologous Stem Cell Transplant clinical trials

View clinical trials related to Autologous Stem Cell Transplant.

Filter by:
  • None
  • Page 1

NCT ID: NCT06377540 Not yet recruiting - Clinical trials for Classic Hodgkin Lymphoma

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.

NCT ID: NCT05358262 Not yet recruiting - Clinical trials for Autologous Stem Cell Transplant

High Heated Humidity in Stem Cell Transplant

Start date: July 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects of high heated humidity has on you and your mucositis.

NCT ID: NCT04783038 Recruiting - Multiple Myeloma Clinical Trials

Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients

Start date: January 27, 2021
Phase: N/A
Study type: Interventional

This research study is being done to determine if Distance Reiki therapy offers a quality of life benefit, and improves immunity compared to patients receiving Sham Distance Reiki therapy or no additional Reiki intervention.

NCT ID: NCT04653246 Recruiting - Multiple Myeloma Clinical Trials

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Start date: July 13, 2021
Phase: Phase 2
Study type: Interventional

This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.

NCT ID: NCT02181413 Active, not recruiting - Multiple Myeloma Clinical Trials

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Start date: July 1, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response [CR], very good partial response [VGPR], or partial response [PR]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).

NCT ID: NCT01296256 Completed - Clinical trials for Autologous Stem Cell Transplant

Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).

BeEAM2010-01
Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Bendamustine in combination with Etoposide, Cytarabine and Melphalan (BeEAM) are effective as conditioning followed by ASCT in patients with aggressive lymphoma.

NCT ID: NCT00291811 Approved for marketing - Clinical trials for Autologous Stem Cell Transplant

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization

CUP
Start date: October 2003
Phase: N/A
Study type: Expanded Access

The purpose of this program is to provide access to AMD3100 for patients who would benefit from an autologous stem cell transplant but who have either previously failed to collect enough cells for transplant following standard therapy or are not considered by their physician to have a reasonable chance of collecting enough cells for transplant.